

# Luis E Raez

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8459163/publications.pdf>

Version: 2024-02-01

187  
papers

9,534  
citations

94433

37  
h-index

39675

94  
g-index

188  
all docs

188  
docs citations

188  
times ranked

12813  
citing authors

#	ARTICLE	IF	CITATIONS
1	Larotrectinib Treatment for Patients With TRK Fusion-Positive Salivary Gland Cancers. <i>Oncologist</i> , 2022, , .	3.7	18
2	Challenges in Genetic Testing and Treatment Outcomes Among Hispanics With Lung Cancer. <i>JCO Oncology Practice</i> , 2022, 18, 374-377.	2.9	3
3	Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti“PD-(L)1 Therapy. <i>Clinical Cancer Research</i> , 2021, 27, 1019-1028.	7.0	58
4	Reaching Across the Aisle: Cardio-Oncology Advocacy and Program Building. <i>Current Oncology Reports</i> , 2021, 23, 64.	4.0	11
5	EGFR L718V (+)/T790M (” as a Mechanism of Resistance in Patients with Metastatic Non”small-cell Lung Cancer with EGFR L858R Mutations. <i>Clinical Lung Cancer</i> , 2021, 22, e817-e819.	2.6	4
6	“STK11“/“TP53“ co-mutated non-small cell lung cancer (NSCLC) to display a unique tumor microenvironment (TME) and metabolic profile.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9087-9087.	1.6	2
7	Risk of development of brain metastases according to the IASLC/ATS/ERS lung adenocarcinoma classification in locally advanced and metastatic disease. <i>Lung Cancer</i> , 2021, 155, 183-190.	2.0	8
8	Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO). <i>Immunotherapy</i> , 2021, 13, 727-734.	2.0	11
9	Characterization of KRAS Mutation Subtypes in Non”small Cell Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 2577-2584.	4.1	66
10	Liquid biopsy from research to clinical practice: focus on non-small cell lung cancer. <i>Expert Review of Molecular Diagnostics</i> , 2021, 21, 1165-1178.	3.1	20
11	Adjuvant therapy in non-small cell lung cancer: is targeted therapy joining the standard of care?. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 1229-1235.	2.4	5
12	Profile of entrectinib in the treatment of ROS1-positive non-small cell lung cancer: Evidence to date. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2021, 14, 192-198.	0.9	4
13	Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1647-1662.	1.1	274
14	Neuregulin 1 Gene (NRG1). A Potentially New Targetable Alteration for the Treatment of Lung Cancer. <i>Cancers</i> , 2021, 13, 5038.	3.7	12
15	Influence of Sex in the Molecular Characteristics and Outcomes of Malignant Tumors. <i>Frontiers in Oncology</i> , 2021, 11, 752918.	2.8	6
16	Using cfRNA as a tool to evaluate clinical treatment outcomes in patients with metastatic lung cancers and other tumors. <i>Cancer Drug Resistance (Alhambra, Calif )</i> , 2021, 4, 1061-1071.	2.1	2
17	Complete Response of Primary Refractory ALK-Positive Large B-Cell Lymphoma Treated With Single-Agent Nivolumab. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e113-e117.	0.4	1
18	Patient-Centered Standards for Medically Integrated Dispensing: ASCO/NCODA Standards. <i>Journal of Clinical Oncology</i> , 2020, 38, 633-644.	1.6	16

#	ARTICLE	IF	CITATIONS
19	Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non-small cell lung cancer (NSCLC) compared with chemotherapy (Quijote-CLICaP). Thoracic Cancer, 2020, 11, 353-361.	1.9	36
20	Lung Cancer in the Young. Lung, 2020, 198, 195-200.	3.3	32
21	Precision Prevention and Cancer Interception: The New Challenges of Liquid Biopsy. Cancer Discovery, 2020, 10, 1635-1644.	9.4	52
22	Recommendations for detection, prioritization, and treatment of thoracic oncology patients during the COVID-19 pandemic: the THOCOoP cooperative group. Critical Reviews in Oncology/Hematology, 2020, 153, 103033.	4.4	17
23	Florida Inter-Specialty Collaborative Project to Improve Cardio-Oncology Awareness and Identify Existing Knowledge Gaps. JACC: CardioOncology, 2020, 2, 535-538.	4.0	10
24	Scientific publications in cancer: in Latin America, strong scientific networks increase productivity (the TENJIN study). Journal of Clinical Epidemiology, 2020, 126, 1-8.	5.0	6
25	Lung Cancer Disparities in Hispanics: Molecular Diagnosis and Use of Immunotherapy. JCO Global Oncology, 2020, 6, 784-788.	1.8	15
26	Lung Cancer in Peru. Journal of Thoracic Oncology, 2020, 15, 891-898.	1.1	4
27	Precision medicine and its implementation in patients with NTRK fusion genes: perspective from developing countries. Therapeutic Advances in Respiratory Disease, 2020, 14, 175346662093855.	2.6	8
28	Review of the Agnostic-Type Treatment Approach: Treating Cancer by Mutations, Not by Location. Oncology and Therapy, 2020, 8, 59-66.	2.6	4
29	Clinical consequences of resistance to ALK inhibitors in non-small cell lung cancer. Expert Review of Respiratory Medicine, 2020, 14, 385-390.	2.5	6
30	Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB). Critical Reviews in Oncology/Hematology, 2020, 151, 102978.	4.4	79
31	Anaphylactic Shock and Cardiac Arrest Secondary to Aprepitant. American Journal of Therapeutics, 2020, 27, e640-e642.	0.9	2
32	A narrative review of biosimilars: a continued journey from the scientific evidence to practice implementation. Translational Lung Cancer Research, 2020, 9, 2113-2119.	2.8	0
33	A narrative review of biosimilars: a continued journey from the scientific evidence to practice implementation. Translational Lung Cancer Research, 2020, 9, 2113-2119.	2.8	5
34	I.18-1 NTRK Fusion Proteins. Journal of Thoracic Oncology, 2019, 14, S1164-S1165.	1.1	0
35	Current knowledge of Ipilimumab and its use in treating non-small cell lung cancer. Expert Opinion on Biological Therapy, 2019, 19, 509-515.	3.1	16
36	I.13-1 New Technologies for Liquid Biopsies and Looking for Cost Effective Options for LATAM (RT-PCR), Tj ETQq0 Q.Q rgBT /Overlock 10	1.1	0

#	ARTICLE	IF	CITATIONS
37	Inhibitor of Differentiation-1 Sustains Mutant <i>KRAS</i> -Driven Progression, Maintenance, and Metastasis of Lung Adenocarcinoma via Regulation of a FOSL1 Network. <i>Cancer Research</i> , 2019, 79, 625-638.	0.9	19
38	Molecular Epidemiology of <i>ALK</i> Rearrangements in Advanced Lung Adenocarcinoma in Latin America. <i>Oncology</i> , 2019, 96, 207-216.	1.9	24
39	The value of immunotherapy in head and neck cancer. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 35-43.	3.1	14
40	RNA-based biomarker signatures in plasma as an independent predictor of outcome to chemotherapy in lung, colon, and breast cancers: Correlation of relative PD-L1 expression with immunotherapy outcomes.. <i>Journal of Clinical Oncology</i> , 2019, 37, e14567-e14567.	1.6	1
41	Exosome-based detection of activating and resistance <i>EGFR</i> mutations from plasma of non-small cell lung cancer patients. <i>Oncotarget</i> , 2019, 10, 2911-2920.	1.8	35
42	Exploiting metabolic susceptibilities in glioblastoma via glycolytic inhibition and ketogenic therapy.. <i>Journal of Clinical Oncology</i> , 2019, 37, e13558-e13558.	1.6	1
43	Clinical responses and survival in Hispanic patients with non-small cell lung cancer treated with immunotherapy compared with non-Hispanic whites.. <i>Journal of Clinical Oncology</i> , 2019, 37, e18109-e18109.	1.6	1
44	Effect of oligometastatic disease management with stereotactic body radiation therapy on survival in patients with metastatic lung cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, e13582-e13582.	1.6	1
45	Abstract 1518: Gene expression profile and gender differences related with immune processes in solid tumors. , 2019, , .		0
46	Efficacy of Larotrectinib in <i>TRK</i> Fusion-Positive Cancers in Adults and Children. <i>New England Journal of Medicine</i> , 2018, 378, 731-739.	27.0	2,036
47	The burden of lung cancer in Latin-America and challenges in the access to genomic profiling, immunotherapy and targeted treatments. <i>Lung Cancer</i> , 2018, 119, 7-13.	2.0	43
48	EGFR-RAD51 Fusion: A Targetable Partnership Originated from the Tumor Evolution?. <i>Journal of Thoracic Oncology</i> , 2018, 13, e33-e34.	1.1	17
49	Gender and outcomes in non-small cell lung cancer: an old prognostic variable comes back for targeted therapy and immunotherapy?. <i>ESMO Open</i> , 2018, 3, e000344.	4.5	105
50	Making Sense of Immunotherapy in Lung Cancer: What the Pulmonologist Needs to Know?. <i>Current Pulmonology Reports</i> , 2018, 7, 42-48.	1.3	0
51	Extracellular Vesicles As miRNA Nano-Shuttles: Dual Role in Tumor Progression. <i>Targeted Oncology</i> , 2018, 13, 175-187.	3.6	31
52	Frequencies and expression levels of programmed death ligand 1 (PD-L1) in circulating tumor RNA (ctRNA) in various cancer types. <i>Biochemical and Biophysical Research Communications</i> , 2018, 500, 621-625.	2.1	44
53	Exosome-Based Detection of <i>EGFR</i> T790M in Plasma from Non-Small Cell Lung Cancer Patients. <i>Clinical Cancer Research</i> , 2018, 24, 2944-2950.	7.0	157
54	Evaluation of weekly paclitaxel plus carboplatin followed by anthracycline chemotherapy on the neoadjuvant treatment of patients with triple-negative breast cancer. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2018, 11, 30-33.	0.9	0

#	ARTICLE	IF	CITATIONS
55	Challenges in Lung Cancer Screening in Latin America. Journal of Global Oncology, 2018, 4, 1-10.	0.5	15
56	Moving osimertinib to first-line: the right "strategy" in the chessboard of epidermal growth factor receptor-mutated non-small cell lung cancer?. Journal of Thoracic Disease, 2018, 10, S1076-S1080.	1.4	5
57	Detection of epidermal growth factor receptor mutations in circulating tumor DNA: reviewing BENEFIT clinical trial. Journal of Thoracic Disease, 2018, 10, 6388-6391.	1.4	5
58	Old myths about old patients: the case of non-small cell lung cancer. Translational Lung Cancer Research, 2018, 7, S362-S363.	2.8	0
59	Pneumonitis in Patients with Lung Cancer Following Treatment: the Effects of Chemotherapy, Immunotherapy, and Tyrosine Kinase Inhibitors. Current Pulmonology Reports, 2018, 7, 214-219.	1.3	0
60	Tumor Type-Agnostic Treatment and the Future of Cancer Therapy. Targeted Oncology, 2018, 13, 541-544.	3.6	7
61	Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC. Journal of Thoracic Oncology, 2018, 13, 1248-1268.	1.1	515
62	Regarding the Congruence Between 2 Circulating Tumor DNA Sequencing Assays. JAMA Oncology, 2018, 4, 1430.	7.1	2
63	ROS-1 Rearrangements in Circulating Tumor Cells. Journal of Thoracic Oncology, 2018, 13, e71-e72.	1.1	9
64	Efficacy and safety of entinostat (ENT) and pembrolizumab (PEMBRO) in patients with non-small cell lung cancer (NSCLC) previously treated with anti-PD-(L)1 therapy.. Journal of Clinical Oncology, 2018, 36, 9036-9036.	1.6	15
65	Use of cell-free circulating RNA (cfRNA) levels in plasma and expression of HER2 and PD-L1 to monitor disease status in metastatic cancer patients.. Journal of Clinical Oncology, 2018, 36, e15013-e15013.	1.6	1
66	Lung cancer immunotherapy outcomes in Hispanic patients.. Journal of Clinical Oncology, 2018, 36, e18665-e18665.	1.6	2
67	Abstract LB-B03: Exosome-based Detection ofEGFRT790M in Plasma from Non-Small Cell Lung Cancer Patients. , 2018, , .		0
68	A Rare Case of Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia. Cureus, 2018, 10, e2525.	0.5	2
69	RNA-Seq data analysis to identify enriched metabolic pathways and a prognostic signature in squamous cell lung cancer.. Journal of Clinical Oncology, 2018, 36, e24288-e24288.	1.6	0
70	Selection of highly stable genes for the transcriptomic evaluation of lung cancer.. Journal of Clinical Oncology, 2018, 36, e24318-e24318.	1.6	0
71	In silico evaluation of DNA Damage Inducible Transcript 4 gene (DDIT4) as prognostic biomarker in several malignancies. Scientific Reports, 2017, 7, 1526.	3.3	60
72	The inhibitor of differentiation-1 (Id1) enables lung cancer liver colonization through activation of an EMT program in tumor cells and establishment of the pre-metastatic niche. Cancer Letters, 2017, 402, 43-51.	7.2	36

#	ARTICLE	IF	CITATIONS
73	P2.03b-039 Cell-Free (cf) DNA and cfRNA levels in Plasma of Lung Cancer Patients Indicate Disease Status and Predict Progression. Journal of Thoracic Oncology, 2017, 12, S959.	1.1	2
74	Immune checkpoint inhibitors in lung cancer: the holy grail has not yet been found. ESMO Open, 2017, 2, e000162.	4.5	19
75	New targets bring hope in squamous cell lung cancer: neurotrophic tyrosine kinase gene fusions. Laboratory Investigation, 2017, 97, 1268-1270.	3.7	20
76	Mutation of MET Y1230 as an Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping. Journal of Thoracic Oncology, 2017, 12, e89-e90.	1.1	34
77	Challenges in Facing the Lung Cancer Epidemic and Treating Advanced Disease in Latin America. Clinical Lung Cancer, 2017, 18, e71-e79.	2.6	23
78	Ceritinib: an orphan drug for ALK positive non-small cell lung cancer with robust clinical evidence. Expert Opinion on Orphan Drugs, 2017, 5, 991-997.	0.8	0
79	Second-Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological, and Molecular Aspects of Nintedanib. Frontiers in Medicine, 2017, 4, 13.	2.6	13
80	Correlation of cell-free circulating DNA, RNA, and PD-L1 from plasma with clinical response in patients with metastatic lung and breast cancers.. Journal of Clinical Oncology, 2017, 35, 11550-11550.	1.6	1
81	Gender and health care outcomes in patients with non-small cell lung cancer: A meta-analysis.. Journal of Clinical Oncology, 2017, 35, e18113-e18113.	1.6	0
82	Impressive Response to Concomitant Platinum-based Chemotherapy and Yttrium-90 in a Patient with Heavily Pretreated Triple-negative Breast Cancer Widely Metastasized to the Liver. Cureus, 2017, 9, e1402.	0.5	0
83	Neurotrophic tyrosine kinase gene fusions: another opportunity for targeting in lung cancer. Lung Cancer Management, 2016, 5, 1-4.	1.5	1
84	Cancer clinical research in Latin America: current situation and opportunities. Expert opinion from the first ESMO workshop on clinical trials, Lima, 2015. ESMO Open, 2016, 1, e000055.	4.5	28
85	3PD Liquid biopsy in patients with adenocarcinoma of the lung and its correlation with their tumor tissue molecular profile. Journal of Thoracic Oncology, 2016, 11, S58.	1.1	1
86	BRAF mutations in non-small cell lung cancer: has finally Janus opened the door?. Critical Reviews in Oncology/Hematology, 2016, 101, 32-39.	4.4	15
87	P1.13 (also presented as PD2.01): Lung Cancer Chromosomal Aberrations and Gene Expression Profiles of Hispanics Living in the US or Latin America are Similar. Journal of Thoracic Oncology, 2016, 11, S187-S188.	1.1	0
88	P1.29: "Real World" Use of Liquid Biopsy in Patients With Lung Adenocarcinoma and Correlation With Tumor Tissue Genetic Profile. Journal of Thoracic Oncology, 2016, 11, S199-S200.	1.1	0
89	PD2.01 (also presented as P1.13): Lung Cancer Chromosomal Aberrations and Gene Expression Profiles of Hispanics Living in the US or Latin America are Similar. Journal of Thoracic Oncology, 2016, 11, S176.	1.1	5
90	The potential of neurotrophic tyrosine kinase (NTRK) inhibitors for treating lung cancer. Expert Opinion on Investigational Drugs, 2016, 25, 385-392.	4.1	26

#	ARTICLE	IF	CITATIONS
91	Comprehensive Genomic Profiling Identifies Frequent Drug-Sensitive EGFR Exon 19 Deletions in NSCLC not Identified by Prior Molecular Testing. <i>Clinical Cancer Research</i> , 2016, 22, 3281-3285.	7.0	33
92	Total mutation burden (TMB) in lung cancer (LC) and relationship with response to PD-1/PD-L1 targeted therapies.. <i>Journal of Clinical Oncology</i> , 2016, 34, 9017-9017.	1.6	129
93	Frequencies and expression levels of programmed death ligand 1 (PD-L1) in circulating tumor RNA (ctRNA) in various cancer types.. <i>Journal of Clinical Oncology</i> , 2016, 34, e23101-e23101.	1.6	1
94	Making steps to decrease emergency room visits in patients with cancer: Our experience after participating in the ASCO Quality Training Program.. <i>Journal of Clinical Oncology</i> , 2016, 34, 51-51.	1.6	2
95	Are the gene expression profiles of Hispanic patients with lung cancer living in the US different from Hispanics living abroad?. <i>Journal of Clinical Oncology</i> , 2016, 34, e18059-e18059.	1.6	0
96	Reducing unnecessary tests in oncology patients using best practice advisories in the Electronic Medical Record.. <i>Journal of Clinical Oncology</i> , 2016, 34, e18239-e18239.	1.6	0
97	Checkpoints inhibitors in first line therapy of metastatic non-small cell lung cancer patients. <i>Translational Cancer Research</i> , 2016, 5, S1443-S1448.	1.0	0
98	cMET in NSCLC: Can We Cut off the Head of the Hydra? From the Pathway to the Resistance. <i>Cancers</i> , 2015, 7, 556-573.	3.7	33
99	Entinostat (SNDX-275) for the treatment of non-small cell lung cancer. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 1101-1109.	4.1	37
100	Nintedanib in non-small cell lung cancer: from preclinical to approval. <i>Therapeutic Advances in Respiratory Disease</i> , 2015, 9, 164-172.	2.6	28
101	Entrectinib: a potent new TRK, ROS1, and ALK inhibitor. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 1493-1500.	4.1	117
102	Preliminary considerations on the use of nintedanib (BIBF 1120) in lung cancer patients. <i>Lung Cancer Management</i> , 2014, 3, 123-126.	1.5	0
103	Immunotherapeutic Agents in Non-small-cell Lung Cancer Finally Coming to the Front Lines. <i>Current Oncology Reports</i> , 2014, 16, 400.	4.0	27
104	Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer?. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 1173-1187.	2.4	25
105	Phase III Randomized Trial of Induction Chemotherapy in Patients With N2 or N3 Locally Advanced Head and Neck Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 2735-2743.	1.6	458
106	Molecular target therapy for bone metastasis: starting a new era with denosumab, a RANKL inhibitor. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 15-26.	3.1	17
107	Overcoming the resistance to Crizotinib in patients with Non-Small Cell Lung Cancer harboring EML4/ALK translocation. <i>Lung Cancer</i> , 2014, 84, 110-115.	2.0	41
108	Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors. <i>Cancer Treatment Reviews</i> , 2014, 40, 990-1004.	7.7	70



#	ARTICLE	IF	CITATIONS
109	Early-stage non-small-cell lung cancer: overview of adjuvant chemotherapy and promising advances. Lung Cancer Management, 2014, 3, 85-99.	1.5	0
110	The Role of cMet in Non-Small Cell Lung Cancer Resistant to EGFRInhibitors: Did We Really Find the Target?. Current Drug Targets, 2014, 15, 1284-1292.	2.1	10
111	ALK and crizotinib: after the honeymoonâ€¦ what else? Resistance mechanisms and new therapies to overcome it. Translational Lung Cancer Research, 2014, 3, 250-61.	2.8	44
112	A phase I dose-escalation trial of 2-deoxy-d-glucose alone or combined with docetaxel in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2013, 71, 523-530.	2.3	362
113	Concurrent chemoradiotherapy versus induction chemotherapy followed by chemoradiotherapy (sequential approach) in the management of head and neck cancer. Expert Review of Anticancer Therapy, 2013, 13, 1065-1072.	2.4	7
114	A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC). Cancer Chemotherapy and Pharmacology, 2013, 72, 1103-1110.	2.3	7
115	A multicenter phase II study of cetuximab in combination with chest radiotherapy and consolidation chemotherapy in patients with stage III non-small cell lung cancer. Lung Cancer, 2013, 81, 416-421.	2.0	21
116	BIBF 1120/nintedanib: a new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer. Expert Opinion on Investigational Drugs, 2013, 22, 1081-1088.	4.1	28
117	Cisplatin and Radiotherapy With or Without Erlotinib in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomized Phase II Trial. Journal of Clinical Oncology, 2013, 31, 1415-1421.	1.6	180
118	Targeting angiogenesis in non-small-cell lung cancer: a focus on current approaches and future developments. Clinical Practice (London, England), 2013, 10, 503-517.	0.1	0
119	Therapeutic vaccines in non-small cell lung cancer. ImmunoTargets and Therapy, 2013, 2, 115.	5.8	5
120	Current Algorithm for Treatment of Advanced NSCLC Patients: How to Include Active Immunotherapy?. Journal of Cancer Therapy, 2013, 04, 59-75.	0.4	1
121	Epidermal growth factor vaccine in non-small-cell lung cancer. Expert Review of Anticancer Therapy, 2012, 12, 439-445.	2.4	9
122	Targeting the Met pathway in lung cancer. Expert Review of Anticancer Therapy, 2012, 12, 519-528.	2.4	27
123	Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck. Oral Oncology, 2012, 48, 887-892.	1.5	42
124	Emerging role of multikinase inhibitors for refractory thyroid cancer. Biologics: Targets and Therapy, 2012, 6, 257.	3.2	9
125	Novel molecular targeted therapies for refractory thyroid cancer. Head and Neck, 2012, 34, 736-745.	2.0	23
126	A phase 1 trial of E7974 administered on day 1 of a 21â€¦day cycle in patients with advanced solid tumors. Cancer, 2012, 118, 4262-4270.	4.1	23



#	ARTICLE	IF	CITATIONS
127	Targeting angiogenesis from multiple pathways simultaneously: BIBF 1120, an investigational novel triple angiokinase inhibitor. <i>Investigational New Drugs</i> , 2012, 30, 1261-1269.	2.6	21
128	Immunotherapy for nonsmall-cell lung cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2012, 5, 90-93.	0.5	3
129	Active immunotherapy for non-small-cell lung cancer: moving toward a reality. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 1599-1605.	2.4	7
130	Efficacy of sorafenib, a multi-tyrosine kinase inhibitor, in an adenoid cystic carcinoma metastatic to the lung: case report and review of literature. <i>Journal of Medical Case Reports</i> , 2011, 5, 483.	0.8	15
131	Development of targeted therapy for squamous cell carcinomas of the head and neck. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 373-386.	2.4	9
132	Phase II Trial of Pemetrexed and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 1140-1145.	1.6	112
133	Immunotherapy as a strategy for the treatment of non-small-cell lung cancer. <i>Therapy: Open Access in Clinical Medicine</i> , 2011, 8, 43-54.	0.2	53
134	The Role of Proteasome Inhibition in Nonsmall Cell Lung Cancer. <i>Journal of Biomedicine and Biotechnology</i> , 2011, 2011, 1-10.	3.0	31
135	A Multicenter, Phase 2 Study of Vascular Endothelial Growth Factor Trap (Aflibercept) in Platinum- and Erlotinib-Resistant Adenocarcinoma of the Lung. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1054-1059.	1.1	84
136	Efficacy and Toxicity of Chemoradiotherapy with Carboplatin and Irinotecan Followed by Consolidation Docetaxel for Unresectable Stage III Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2010, 5, 533-539.	1.1	17
137	Nasopharyngeal carcinoma: alternative treatment options after disease progression. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 377-386.	2.4	16
138	EGF receptor in lung cancer: a successful story of targeted therapy. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 1577-1587.	2.4	12
139	Accelerated second-line or maintenance chemotherapy versus treatment at disease progression in NSCLC. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 549-557.	2.4	1
140	Oxaliplatin in First-line Therapy for Advanced Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2010, 11, 18-24.	2.6	36
141	Tumor immunogenicity and responsiveness to cancer vaccine therapy: The state of the art. <i>Seminars in Immunology</i> , 2010, 22, 105-112.	5.6	44
142	Developing a Vaccine for Non-Small-Cell Lung Cancer. <i>Postgraduate Medicine</i> , 2009, 121, 187-189.	2.0	1
143	How is gene-expression profiling going to challenge the future management of lung cancer?. <i>Future Oncology</i> , 2009, 5, 827-835.	2.4	8
144	Cancer vaccines: a new therapeutic alternative for lung cancer therapy?. <i>Immunotherapy</i> , 2009, 1, 727-728.	2.0	0

#	ARTICLE	IF	CITATIONS
145	Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation. <i>Annals of Oncology</i> , 2009, 20, 921-927.	1.2	134
146	Second-Line Therapy for Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2009, 10, 91-98.	2.6	5
147	Gene Expression Profiling and Non-Small-Cell Lung Cancer: Where Are We Now?. <i>Clinical Lung Cancer</i> , 2009, 10, 168-173.	2.6	18
148	Radiation technique influence on percutaneous endoscopic gastrostomy tube dependence: Comparison between two radiation schemes. <i>Head and Neck</i> , 2009, 31, 944-948.	2.0	6
149	Epidermal growth factor receptor pathway as therapeutic development in head and neck cancers: present and future. <i>Oncology Reviews</i> , 2009, 3, 137-148.	1.8	1
150	Abstract B206: Pharmacokinetic and pharmacodynamic analysis of patients treated with the histone deacetylase inhibitor entinostat in combination with erlotinib. , 2009, , .		0
151	Controversies in the management of stage IIIA non-small-cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 1913-1929.	2.4	5
152	Targeting important pathways in head and neck cancer: from the bench to the clinic. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 1819-1835.	2.4	2
153	Efficacy and Safety of Oxaliplatin and Gemcitabine with Bevacizumab in Advanced Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2008, 3, 511-515.	1.1	24
154	Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer. <i>New England Journal of Medicine</i> , 2007, 357, 1705-1715.	27.0	1,537
155	New targets for non-small-cell lung cancer therapy. <i>Expert Review of Anticancer Therapy</i> , 2007, 7, 1423-1437.	2.4	35
156	Allogeneic tumor-cell-based vaccines secreting endoplasmic reticulum chaperone gp96. <i>Expert Opinion on Biological Therapy</i> , 2007, 7, 1679-1688.	3.1	15
157	EGFR Targeting of Solid Tumors. <i>Cancer Control</i> , 2007, 14, 295-304.	1.8	245
158	M17-01: Immunotherapy for lung tumors. <i>Journal of Thoracic Oncology</i> , 2007, 2, S197-S198.	1.1	0
159	Intensity-Modulated Radiotherapy With Concurrent Chemotherapy for Previously Irradiated, Recurrent Head and Neck Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, 1067-1073.	0.8	80
160	Current results and future applications of radioimmunotherapy management of non-Hodgkin's lymphoma. <i>Leukemia and Lymphoma</i> , 2006, 47, 2453-2476.	1.3	13
161	Heat Shock Protein-Based Cancer Vaccines. <i>Hematology/Oncology Clinics of North America</i> , 2006, 20, 637-659.	2.2	17
162	Advantage of EUS Trucut biopsy combined with fine-needle aspiration without immediate on-site cytopathologic examination. <i>Gastrointestinal Endoscopy</i> , 2006, 64, 505-511.	1.0	109

#	ARTICLE	IF	CITATIONS
163	Does EUS Trucut Biopsy (TCB) Plus Fine Needle Aspiration (FNA) Increase Accuracy Over FNA in Thoracic Disease When No On-Site Cytopathologist Is Present?. <i>Gastrointestinal Endoscopy</i> , 2006, 63, AB276.	1.0	0
164	Pemetrexed-associated urticarial vasculitis. <i>Lung Cancer</i> , 2006, 51, 247-249.	2.0	31
165	Efficacy and safety of oxaliplatin and docetaxel in patients with locally advanced and metastatic non-small-cell lung cancer (NSCLC). <i>Lung Cancer</i> , 2006, 53, 347-353.	2.0	19
166	New developments in chemotherapy for advanced non-small cell lung cancer. <i>Current Opinion in Internal Medicine</i> , 2006, 5, 305-310.	1.5	15
167	Successful treatment of autoimmune hepatitis and idiopathic thrombocytopenic purpura with the monoclonal antibody, rituximab: case report and review of literature. <i>Liver International</i> , 2006, 26, 625-629.	3.9	58
168	Present and future of lung cancer vaccines. <i>Expert Opinion on Emerging Drugs</i> , 2006, 11, 445-459.	2.4	8
169	Randomized Phase II Study of Bortezomib Alone and Bortezomib in Combination With Docetaxel in Previously Treated Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 5025-5033.	1.6	154
170	Induction chemotherapy in the management of squamous cell carcinoma of the head and neck. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 1205-1215.	2.4	11
171	Combined modality therapy for limited-disease small cell lung cancer. <i>Current Treatment Options in Oncology</i> , 2005, 6, 69-74.	3.0	8
172	DNA methylation: its role in lung carcinogenesis and therapeutic implications. <i>Expert Review of Anticancer Therapy</i> , 2005, 5, 667-679.	2.4	3
173	Clinical Responses to Gefinitib After Failure of Treatment With Cetuximab in Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 4244-4245.	1.6	10
174	Lung Cancer Immunotherapy. <i>Clinical Medicine and Research</i> , 2005, 3, 221-228.	0.8	58
175	Combination of imatinib and cytarabine for the treatment of Philadelphia chromosome positive acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2005, 46, 297-298.	1.3	2
176	Clinical trials targeting lung cancer with active immunotherapy: the scope of vaccines. <i>Expert Review of Anticancer Therapy</i> , 2005, 5, 635-644.	2.4	9
177	Allogeneic Vaccination With a B7.1 HLA-A Gene-Modified Adenocarcinoma Cell Line in Patients With Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2004, 22, 2800-2807.	1.6	103
178	Irinotecan and docetaxel as first line chemotherapy in patients with stage IIIB/IV non-small cell lung cancer—experience from a prematurely closed phase II study. <i>Lung Cancer</i> , 2004, 45, 131-132.	2.0	8
179	The Utility of a Bone Marrow Biopsy in Diagnosing the Source of Fever of Unknown Origin in Patients With AIDS. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2004, 37, 1599-1603.	2.1	14
180	Chemotherapy for advanced non-small-cell lung cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2004, 2, 173-8.	0.3	21

#	ARTICLE	IF	CITATIONS
181	Induction of CD8 T-cell-Ifn- $\gamma$ response and positive clinical outcome after immunization with gene-modified allogeneic tumor cells in advanced non-small-cell lung carcinoma. Cancer Gene Therapy, 2003, 10, 850-858.	4.6	27
182	Primary Hepatic Non-Hodgkin's Lymphomas: Case Report and Review of The Literature. American Journal of Gastroenterology, 2003, 98, 2789-2793.	0.4	49
183	Radical Resection of Periapillary Tumors in the Elderly: Evaluation of Long-term Results. World Journal of Surgery, 2000, 24, 353-358.	1.6	73
184	Treatment of AIDS-Related Primary Central Nervous System Lymphoma with Zidovudine, Ganciclovir, and Interleukin 2. AIDS Research and Human Retroviruses, 1999, 15, 713-719.	1.1	89
185	Pulmonary Bone Marrow Embolism in Sickle Cell Disease. Southern Medical Journal, 1999, 92, 245-247.	0.7	13
186	Successful treatment of lymphomatoid granulomatosis using cyclosporin-A after failure of intensive chemotherapy. , 1996, 53, 192-195.		6
187	Durvalumab After Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer: Inferior Outcomes and Lack of Health Equity in Hispanic Patients Treated With PACIFIC Protocol (LA1-CLICaP). Frontiers in Oncology, 0, 12, .	2.8	4